PTGX Is the Most Shorted Name Among Its Closest Peers

Protagonist Therapeutics stands out in its peer group this week for the wrong reason: its short interest, at 15.2% of free float, is the most heavily shorted position among its closest correlated names. Against a median one-week gain of 2.6% for peers including RYTM, BNTC, and STOK, PTGX slipped 0.4% to $137.99, a divergence that makes the short positioning the clearest story in the stock right now.

That short position has been building steadily and is now at its highest level in at least a year. Shares short climbed 22% over the past month, from roughly 7.8 million in mid-September to 9.5 million this week. The weekly uptick is modest at 1.6%, but the monthly trend is unambiguous: short sellers have been adding conviction through the autumn. The borrow market, however, is not under stress. Availability remains loose at 526%, meaning there are more than five shares available to borrow for every one currently lent out, well above the 52-week tightest reading of 408%. Cost to borrow is running at 0.52%, near the low end of the past month's range. No squeeze pressure exists in the lending market, and new shorts face no material friction getting on.

The Street is pointing in the opposite direction from the shorts, and the gap is notable. TD Cowen raised its target to $160 from $155 today, maintaining its Buy rating. UBS initiated with a Buy at $184 on October 12, and Leerink Partners assumed coverage the same day with an Outperform and a $190 target. The consensus mean target of $178.57 implies roughly 29% upside from current levels, and the analyst recommendation divergence factor scores in the 92nd percentile relative to the broader universe. Bulls point to icotrokinra's commercial momentum, over 18,000 prescriptions written by 7,000 physicians, and a potential $8.3 billion peak opportunity in psoriasis alone. Bears flag the dependency on Johnson & Johnson and Takeda for commercial execution, along with pipeline execution risk in the wholly owned assets. The PE multiple has expanded to 173x over the past 30 days, adding 52 points in a month, which frames the valuation stretch that may be keeping short interest elevated even as the Street turns more bullish.

Insider activity is worth noting for context rather than conviction. The CEO and CFO both filed sales in September under pre-arranged 10b5-1 plans. Net insider activity over the past 90 days amounts to a $41 million net outflow on 283,000 shares. Because these were plan-driven transactions rather than discretionary sales, they carry limited informational weight. More structurally relevant is the ownership register: BlackRock holds 15.9% and added 528,000 shares in Q3, while T. Rowe Price added 484,000 shares in the same period. Johnson & Johnson Innovation holds 3.8%, a commercial alignment that underpins the royalty thesis. No 13D activists are on the register. All 13D/G positions are as last disclosed and stakes below 5% may exit without a further filing.

ORTEX puts the probability of PTGX graduating from the Russell 2000 to the Russell 1000 at the December 2026 Semi-Annual Review at 25%. The stock needs to close above $151.63 to qualify at the rank date of October 30. At the current price of $137.99, that requires a 9.9% move in nine days. The flow attached to an addition would be $425 million of buying from index trackers, equivalent to 4.8 days of normal volume. The paired deletion from the Russell 2000 would trigger $1.2 billion of selling, 13.1 days of volume. Both rows carry identical 25% probability and will be decided by the same market cap rank. Among 120 past comparable additions, the median move from announcement to effective date was negative 3.6%, and only 32% of additions moved in the expected direction, per ORTEX history.

The picture heading into the November 2 earnings report is a genuine divergence between short sellers adding positions and analysts lifting targets. The level that would most change that picture is whether short interest begins to retrace below 9 million shares, which was the approximate level before the October build began.